ASSESSMENT OF PERFORMANCE AND IMPLEMENTATION CHARACTERISTICS OF RAPID POINT OF CARE SARS-CoV-2 ANTIGEN TESTING IN KENYA

Q2 Multidisciplinary AAS Open Research Pub Date : 2021-06-06 DOI:10.1101/2021.06.03.21258290
Eva Muthamia, S. Mungai, M. Mungai, G. Bandawe, F. Qadri, Z. Kawser, S. Lockman, L. Ivers, D. Walt, S. Suliman, M. Mwau, J. Gitaka
{"title":"ASSESSMENT OF PERFORMANCE AND IMPLEMENTATION CHARACTERISTICS OF RAPID POINT OF CARE SARS-CoV-2 ANTIGEN TESTING IN KENYA","authors":"Eva Muthamia, S. Mungai, M. Mungai, G. Bandawe, F. Qadri, Z. Kawser, S. Lockman, L. Ivers, D. Walt, S. Suliman, M. Mwau, J. Gitaka","doi":"10.1101/2021.06.03.21258290","DOIUrl":null,"url":null,"abstract":"Abstract Background: The COVID-19 pandemic has resulted in a need for rapid identification of infectious cases. Testing barriers have prohibited adequate screening for SARS COV2, resulting in significant delays in treatment provision and commencement of outbreak control measures. This study aimed to generate evidence on the performance and implementation characteristics of the BD Veritor rapid antigen test as compared to the gold standard test for diagnosis of SARS COV2 in Kenya. Methods: This was a field test performance evaluation in symptomatic and asymptomatic adults undergoing testing for SARS COV2. Recruited participants were classified as SARS-CoV2-positive based on the locally implemented gold standard reverse transcription polymerase chain reaction (RT-PCR) test performed on nasopharyngeal swabs. 272 antigen tests were performed with simultaneous gold standard testing, allowing us to estimate sensitivity, specificity, positive and negative predictive values for the BD Veritor rapid antigen test platform. Implementation characteristics were assessed using the Consolidated Framework for Implementation Research for feasibility, acceptability, turn-around time, and ease-of-use metrics. Results and Discussion: We enrolled 97 PCR negative symptomatic and 128 PCR negative asymptomatic, and 28 PCR positive symptomatic and 19 PCR positive asymptomatic participants. Compared to the gold standard, the sensitivity of the BD Veritor antigen test was 94% (95% confidence interval [CI] 86.6 to 100.0) while the specificity was 98% (95% confidence interval [CI] 96 to 100). The sensitivity of BD Veritor antigen test was higher among symptomatic (100%) compared to asymptomatic (84%) participants, although this difference was not statistically significant. There was also a lack of association between cycle threshold value and sensitivity of BD Veritor test. The BD Veritor test had quick turnaround time and minimal resource requirements, and laboratory personnel conducting testing felt that it was easier to use than the gold standard RT-PCR. Conclusion: The BD Veritor rapid antigen test exhibited excellent sensitivity and specificity when used to detect SARS-CoV-2 infection among both symptomatic and asymptomatic individuals in varied population settings in Kenya. It was feasible to implement and easy to use, with rapid turnaround time.","PeriodicalId":34179,"journal":{"name":"AAS Open Research","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AAS Open Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2021.06.03.21258290","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Multidisciplinary","Score":null,"Total":0}
引用次数: 5

Abstract

Abstract Background: The COVID-19 pandemic has resulted in a need for rapid identification of infectious cases. Testing barriers have prohibited adequate screening for SARS COV2, resulting in significant delays in treatment provision and commencement of outbreak control measures. This study aimed to generate evidence on the performance and implementation characteristics of the BD Veritor rapid antigen test as compared to the gold standard test for diagnosis of SARS COV2 in Kenya. Methods: This was a field test performance evaluation in symptomatic and asymptomatic adults undergoing testing for SARS COV2. Recruited participants were classified as SARS-CoV2-positive based on the locally implemented gold standard reverse transcription polymerase chain reaction (RT-PCR) test performed on nasopharyngeal swabs. 272 antigen tests were performed with simultaneous gold standard testing, allowing us to estimate sensitivity, specificity, positive and negative predictive values for the BD Veritor rapid antigen test platform. Implementation characteristics were assessed using the Consolidated Framework for Implementation Research for feasibility, acceptability, turn-around time, and ease-of-use metrics. Results and Discussion: We enrolled 97 PCR negative symptomatic and 128 PCR negative asymptomatic, and 28 PCR positive symptomatic and 19 PCR positive asymptomatic participants. Compared to the gold standard, the sensitivity of the BD Veritor antigen test was 94% (95% confidence interval [CI] 86.6 to 100.0) while the specificity was 98% (95% confidence interval [CI] 96 to 100). The sensitivity of BD Veritor antigen test was higher among symptomatic (100%) compared to asymptomatic (84%) participants, although this difference was not statistically significant. There was also a lack of association between cycle threshold value and sensitivity of BD Veritor test. The BD Veritor test had quick turnaround time and minimal resource requirements, and laboratory personnel conducting testing felt that it was easier to use than the gold standard RT-PCR. Conclusion: The BD Veritor rapid antigen test exhibited excellent sensitivity and specificity when used to detect SARS-CoV-2 infection among both symptomatic and asymptomatic individuals in varied population settings in Kenya. It was feasible to implement and easy to use, with rapid turnaround time.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肯尼亚快速护理点SARS-CoV-2抗原检测的效果和实施特点评估
摘要背景:新冠肺炎大流行导致需要快速识别传染性病例。检测障碍阻碍了对严重急性呼吸系统综合征冠状病毒2型的充分筛查,导致治疗提供和疫情控制措施的启动出现重大延误。本研究旨在为BD Veritor快速抗原测试与肯尼亚诊断严重急性呼吸系统综合征冠状病毒2型的金标准测试的性能和实施特征提供证据。方法:这是对接受严重急性呼吸系统综合征冠状病毒2型检测的有症状和无症状成年人的现场检测性能评估。根据对鼻咽拭子进行的本地金标准逆转录聚合酶链式反应(RT-PCR)检测,招募的参与者被归类为严重急性呼吸系统综合征冠状病毒2型阳性。272项抗原测试同时进行金标准测试,使我们能够估计BD Veritor快速抗原测试平台的敏感性、特异性、阳性和阴性预测值。使用实施研究综合框架评估实施特征的可行性、可接受性、周转时间和易用性指标。结果与讨论:我们招募了97名PCR阴性症状和128名PCR阴性无症状参与者,以及28名PCR阳性症状和19名PCR阳性无症状参与者。与金标准相比,BD Veritor抗原测试的灵敏度为94%(95%置信区间[CI]86.6至100.0),而特异性为98%(95%置信间隔[CI]96至100)。BD Veritor抗原检测的敏感性在有症状的参与者中(100%)高于无症状的参与者(84%),尽管这一差异在统计学上并不显著。BD Veritor测试的周期阈值和灵敏度之间也缺乏相关性。BD Veritor测试具有快速的周转时间和最低的资源要求,进行测试的实验室人员认为它比金标准RT-PCR更容易使用。结论:BD Veritor快速抗原检测在肯尼亚不同人群中用于检测有症状和无症状个体的严重急性呼吸系统综合征冠状病毒2型感染时表现出优异的敏感性和特异性。它实施可行,易于使用,周转时间短。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
AAS Open Research
AAS Open Research Multidisciplinary-Multidisciplinary
CiteScore
2.90
自引率
0.00%
发文量
16
审稿时长
6 weeks
期刊最新文献
Delays in initiating rabies post-exposure prophylaxis among dog bite victims in Wakiso and Kampala districts, Uganda. Stigma-directed services (Stig2Health) to improve 'linkage to care' for people living with HIV in rural Tanzania: study protocol for a nested pre-post implementation study within the Kilombero and Ulanga Antiretroviral Cohort. Case studies from the experience of early career researchers in East Africa in building community engagement in research. Small area estimation for South African resource distribution and policy impacts during COVID-19 Building community and public engagement in research – the experience of early career researchers in East Africa
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1